Last reviewed · How we verify
Gemcitabine - 21 day cycle
Inhibits DNA synthesis by inhibiting ribonucleotide reductase and DNA polymerase alpha
Inhibits DNA synthesis by inhibiting ribonucleotide reductase and DNA polymerase alpha Used for Pancreatic cancer, Breast cancer, Non-small cell lung cancer.
At a glance
| Generic name | Gemcitabine - 21 day cycle |
|---|---|
| Also known as | Gemzar |
| Sponsor | Actuate Therapeutics Inc. |
| Drug class | Nucleoside analog |
| Target | Ribonucleotide reductase |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Gemcitabine is a nucleoside analog that is phosphorylated to its active form, which then inhibits ribonucleotide reductase and DNA polymerase alpha, leading to DNA chain termination and apoptosis in rapidly dividing cells.
Approved indications
- Pancreatic cancer
- Breast cancer
- Non-small cell lung cancer
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
Key clinical trials
- Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer (PHASE1)
- Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial (PHASE2)
- Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2) (PHASE2, PHASE3)
- A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003) (PHASE2, PHASE3)
- Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma (PHASE1, PHASE2)
- Durvalumab With Gemcitabine and Cisplatin for the Treatment of High-Risk Resectable Liver Cancer Before Surgery (PHASE2)
- Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer (PHASE2)
- Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Gemcitabine - 21 day cycle CI brief — competitive landscape report
- Gemcitabine - 21 day cycle updates RSS · CI watch RSS
- Actuate Therapeutics Inc. portfolio CI